Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.

Bevacizumab and Chemotherapy Remains Standard of Care in RAS/RAF Mutated mCRC

August 04, 2022

In an interview with Targeted Oncology, Christopher Nevala-Plagemann, MD, discussed the key takeaways of his research on the best treatment strategies for patients with left sided RAS or RAF wild-type metastatic colorectal cancer.